Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia

Auro Del Giglio, Susan O'Brien, Richard Ford, Hideyuki Saya, John Manning, Michael Keating, Dennis Johnston, Rainer Khetan, Adel El-Naggar, Albert Deisseroth

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia (CLL) is a usually indolent disease that can assume an aggressive clinical course in some patients. To develop assays that would be predictive of how a particular patient's disease would evolve, we studied the expression of proliferating cell nuclear antigen (PCNA) by Western blotting in 40 patients with CLL. The concentration of PCNA, a cofactor for δDNA-dependent DNA polymerase, is indicative of the proliferative state of the cell. Significantly lower PCNA levels were observed in earlier stage CLL when compared with more advanced disease. The leukemic cell proliferative rate, assessed by lymphocyte doubling time and flow cytometry, also correlated significantly with the level of PCNA expression. These results suggest that a high level of PCNA in the cells of CLL patients at presentation identifies a subgroup of patients whose CLL cells have a higher proliferative activity and who may, therefore, have a potentially shorter survival.

Original languageEnglish
Pages (from-to)2717-2720
Number of pages4
JournalBlood
Volume79
Issue number10
Publication statusPublished - 1992 May 15
Externally publishedYes

Fingerprint

Lymphoid Leukemia
Proliferating Cell Nuclear Antigen
B-Cell Chronic Lymphocytic Leukemia
Lymphocytes
Flow cytometry
DNA-Directed DNA Polymerase
Assays
Flow Cytometry
Western Blotting
Survival

ASJC Scopus subject areas

  • Hematology

Cite this

Del Giglio, A., O'Brien, S., Ford, R., Saya, H., Manning, J., Keating, M., ... Deisseroth, A. (1992). Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood, 79(10), 2717-2720.

Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. / Del Giglio, Auro; O'Brien, Susan; Ford, Richard; Saya, Hideyuki; Manning, John; Keating, Michael; Johnston, Dennis; Khetan, Rainer; El-Naggar, Adel; Deisseroth, Albert.

In: Blood, Vol. 79, No. 10, 15.05.1992, p. 2717-2720.

Research output: Contribution to journalArticle

Del Giglio, A, O'Brien, S, Ford, R, Saya, H, Manning, J, Keating, M, Johnston, D, Khetan, R, El-Naggar, A & Deisseroth, A 1992, 'Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia', Blood, vol. 79, no. 10, pp. 2717-2720.
Del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M et al. Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood. 1992 May 15;79(10):2717-2720.
Del Giglio, Auro ; O'Brien, Susan ; Ford, Richard ; Saya, Hideyuki ; Manning, John ; Keating, Michael ; Johnston, Dennis ; Khetan, Rainer ; El-Naggar, Adel ; Deisseroth, Albert. / Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. In: Blood. 1992 ; Vol. 79, No. 10. pp. 2717-2720.
@article{4deb8ce479054ed8872052c78c9b167e,
title = "Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia",
abstract = "Chronic lymphocytic leukemia (CLL) is a usually indolent disease that can assume an aggressive clinical course in some patients. To develop assays that would be predictive of how a particular patient's disease would evolve, we studied the expression of proliferating cell nuclear antigen (PCNA) by Western blotting in 40 patients with CLL. The concentration of PCNA, a cofactor for δDNA-dependent DNA polymerase, is indicative of the proliferative state of the cell. Significantly lower PCNA levels were observed in earlier stage CLL when compared with more advanced disease. The leukemic cell proliferative rate, assessed by lymphocyte doubling time and flow cytometry, also correlated significantly with the level of PCNA expression. These results suggest that a high level of PCNA in the cells of CLL patients at presentation identifies a subgroup of patients whose CLL cells have a higher proliferative activity and who may, therefore, have a potentially shorter survival.",
author = "{Del Giglio}, Auro and Susan O'Brien and Richard Ford and Hideyuki Saya and John Manning and Michael Keating and Dennis Johnston and Rainer Khetan and Adel El-Naggar and Albert Deisseroth",
year = "1992",
month = "5",
day = "15",
language = "English",
volume = "79",
pages = "2717--2720",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia

AU - Del Giglio, Auro

AU - O'Brien, Susan

AU - Ford, Richard

AU - Saya, Hideyuki

AU - Manning, John

AU - Keating, Michael

AU - Johnston, Dennis

AU - Khetan, Rainer

AU - El-Naggar, Adel

AU - Deisseroth, Albert

PY - 1992/5/15

Y1 - 1992/5/15

N2 - Chronic lymphocytic leukemia (CLL) is a usually indolent disease that can assume an aggressive clinical course in some patients. To develop assays that would be predictive of how a particular patient's disease would evolve, we studied the expression of proliferating cell nuclear antigen (PCNA) by Western blotting in 40 patients with CLL. The concentration of PCNA, a cofactor for δDNA-dependent DNA polymerase, is indicative of the proliferative state of the cell. Significantly lower PCNA levels were observed in earlier stage CLL when compared with more advanced disease. The leukemic cell proliferative rate, assessed by lymphocyte doubling time and flow cytometry, also correlated significantly with the level of PCNA expression. These results suggest that a high level of PCNA in the cells of CLL patients at presentation identifies a subgroup of patients whose CLL cells have a higher proliferative activity and who may, therefore, have a potentially shorter survival.

AB - Chronic lymphocytic leukemia (CLL) is a usually indolent disease that can assume an aggressive clinical course in some patients. To develop assays that would be predictive of how a particular patient's disease would evolve, we studied the expression of proliferating cell nuclear antigen (PCNA) by Western blotting in 40 patients with CLL. The concentration of PCNA, a cofactor for δDNA-dependent DNA polymerase, is indicative of the proliferative state of the cell. Significantly lower PCNA levels were observed in earlier stage CLL when compared with more advanced disease. The leukemic cell proliferative rate, assessed by lymphocyte doubling time and flow cytometry, also correlated significantly with the level of PCNA expression. These results suggest that a high level of PCNA in the cells of CLL patients at presentation identifies a subgroup of patients whose CLL cells have a higher proliferative activity and who may, therefore, have a potentially shorter survival.

UR - http://www.scopus.com/inward/record.url?scp=0026723767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026723767&partnerID=8YFLogxK

M3 - Article

VL - 79

SP - 2717

EP - 2720

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -